Home / Health / Indian Pharma Milestone: First Novel Antibiotic Gets FDA Nod
Indian Pharma Milestone: First Novel Antibiotic Gets FDA Nod
24 Jun
Summary
- India's Wockhardt received US FDA approval for a novel antibiotic.
- ZAYNICH targets severe Gram-negative bacterial infections, a growing threat.
- This marks a significant achievement for India's pharmaceutical research.
India's pharmaceutical sector has reached a significant milestone with Wockhardt's ZAYNICH™ receiving US FDA approval on May 30, 2026. This novel intravenous antibiotic is designed to combat complicated urinary tract infections caused by resistant Gram-negative bacteria. The development process spanned 17 years, involving approximately 200 researchers at Wockhardt's facility in Chhatrapati Sambhajinagar.
This achievement is particularly notable as it represents the first instance of a new chemical entity, fully discovered and developed by an Indian pharmaceutical company, securing US FDA approval. The drug's approval comes at a critical time when antimicrobial resistance is recognized as a major global public health challenge. Most large pharmaceutical firms have reduced their focus on antibiotic research due to lower commercial returns.
ZAYNICH™ was evaluated in a Phase III trial involving 530 patients across 64 sites globally, including India. The drug also received approval from India's Drugs Controller General on May 27, 2026. Wockhardt plans to price the drug significantly lower in India compared to its estimated $12,000-$15,000 cost in the US.
The company has applied for marketing authorization in Europe, with expectations of broader approvals for other serious Gram-negative infections like pneumonia and bloodstream infections. This drug is administered intravenously and will be available in hospitals. In compassionate-use cases prior to approval, ZAYNICH™ demonstrated high survival rates, with over 90% of patients treated showing positive outcomes.
